Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Forecasted
This grant funds projects to further develop and validate innovative technologies that advance cancer research or clinical care, focusing on technical improvements and rigorous validation for broad adoption.
Browse similar grants
Funder: National Institutes of Health
Due Dates (Anticipated): June 2027 (Full application deadline, projected)
Funding Amounts: $300,000 per award (up to 14 awards); total program funding estimated at $6.6 million
Summary: Supports further development and rigorous validation of innovative technologies for basic and clinical cancer research, focused on accelerating advances in cancer biology, detection, diagnosis, and care.
Key Information: This is a forecasted opportunity; dates and details are subject to change.
Description
This funding opportunity, administered by the National Cancer Institute (NCI) under the NIH, supports R33 grant applications for the advanced development and validation of emerging technologies aimed at basic and clinical cancer research. The program seeks projects where feasibility has already been demonstrated with preliminary data, but where further technical development, optimization, and validation are needed to enable widespread adoption by the cancer research community.
Eligible projects should propose new or significantly improved technologies with the potential to advance cancer biology, early detection, screening, diagnosis, treatment, cancer control, or epidemiology. Areas of interest include, but are not limited to:
- Advanced molecular and cellular analysis platforms
- Multi-omic and spatial profiling methods
- Imaging and sensing technologies
- Immuno-engineering approaches
- Innovations in biospecimen processing, modeling, and quality assessment
Projects must focus on cancer-related applications. Proposals that simply apply existing technologies to new clinical or biological questions, without technological innovation, are not appropriate. This opportunity is part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program.
